This was the stock's third consecutive day of losses.
Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...
Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...
O'Melveny & Myers is defending Abbott Laboratories in a pending class action against the company and two other ...
Cardiovascular disease is rising, and Abbott Laboratories is well-positioned in the CVD treatment space. Read why I'm neutral ...
Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...
Abbott Laboratories' (NYSE:ABT) stock up by 8.7% over the past three months. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s fundamentals to ...
Abbott Laboratories closed $4.01 short of its 52-week high ($121.64), which the company reached on March 8th.
Abbott Drive can’t seem to get enough of the orange construction cones. For the second time this year, the Omaha Airport ...
Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the ...